Spineway SA reported full year 2025 revenue of EUR 12.43 million, up 4%. Gross margin was EUR 8.65 million, representing 69.6% of revenue. Net operating expenses totaled EUR 10.78 million. The operating loss was EUR 2.1 million. Net cash stood at EUR 2 million as of December 31, 2025, with financial debt reduced to EUR 1.5 million. During the period, Spineway consolidated its geographic diversification, launched production of its ESP1 disc prosthesis, and continued investments in regulatory approvals and clinical studies. The company highlighted that synergies from the acquisitions of Distimp and Spine Innovation have nearly tripled consolidated revenue since 2021 and strengthened growth potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spineway SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001165257-en) on February 17, 2026, and is solely responsible for the information contained therein.